US20080234353A1 - Formulations of Ramipril - Google Patents
Formulations of Ramipril Download PDFInfo
- Publication number
- US20080234353A1 US20080234353A1 US10/593,627 US59362705A US2008234353A1 US 20080234353 A1 US20080234353 A1 US 20080234353A1 US 59362705 A US59362705 A US 59362705A US 2008234353 A1 US2008234353 A1 US 2008234353A1
- Authority
- US
- United States
- Prior art keywords
- amount
- ramipril
- tablet formulation
- compactrol
- hydrogen carbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HDACQVRGBOVJII-JBDAPHQKSA-N [H][C@@]12CCC[C@]1([H])N(C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC)[C@H](C(=O)O)C2 Chemical compound [H][C@@]12CCC[C@]1([H])N(C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC)[C@H](C(=O)O)C2 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Definitions
- the present invention relates to stable pharmaceutical formulations of ramipril, optionally in combination with a diuretic.
- Ramipril, (2S,3aS,6aS)-1[(S)—N—[(S)-1-carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, 1-ethyl ester is an angiotensin converting enzyme (ACE) inhibitor.
- ACE angiotensin converting enzyme
- Ramipril can undergo cyclization via internal nucleophilic attack to form substituted diketopiperazines and also degrade via hydrolysis and oxidation.
- EP 1 501 546 A1 describes stable pharmaceutical formulation for combinations of a statin and an ACE inhibitor.
- the problem underlying the invention is that if an ACE inhibitor is in the presence of a stabilised statin, the ACE inhibitor decomposes to such extent that even after short storage period the content of decomposition products exceeds the permissible limit of degradation.
- EP 1 501 546 A1 provides a formulation wherein the statin and the ACE inhibitor are separated by physiologically acceptable inert material. Calcium sulfate is mentioned as a possible inorganic filler in the formulation but it is neither claimed nor mentioned in any example. In fact all the examples are concerned with three-layer tablet, wherein the statin layer and ACE inhibitor layer are separated by a layer of microcrystalline cellulose. Combinations of the ACE inhibitor with a diuretic are not mentioned.
- US 2003/0215526 claims formulations of ACE inhibitor a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of an ACE inhibitor which is susceptible to degradation or its salt; a greater than stoichiometric amount of an alkali or alkaline earth metal carbonate, relative to the amount of ACE inhibitor or its salt, and a pharmaceutically acceptable carrier.
- the excipient calcium sulphate is not mentioned.
- EP 0 280 999 B1 describes a composition comprising ACE inhibitor (i.e. ramipril), an alkali or alkaline earth metal carbonate and saccharide wherein the ACE inhibitor is stabilized against degradation (cyclization, discoloration and hydrolysis) by means of the other mentioned ingredients.
- ACE inhibitor i.e. ramipril
- alkali or alkaline earth metal carbonate i.e. alumipril
- saccharide i.e. ramipril
- saccharide i.e. ramipril
- lactose and mannitol mannitol
- Modified starch is mentioned as disintegrant in the specification.
- EP 0 317 878 B1 claims a stable, compressed pharmaceutical formulation containing a compound of a defined formula (i.e. ramipril) wherein, for stabilization before compression, a compound of the formula is a) coated with a polymeric, physiologically tolerated protective coating, or b) mixed with a physiologically tolerated buffer which ensures that a pH in the weakly acidic to weakly alkaline range is set up in a pharmaceutical formulation in the presence of moisture, where sodium bicarbonate is excepted as buffer, or c) mixed with a physiologically tolerated buffer which ensures that a pH in the weakly acid to weakly alkaline range is set up in a pharmaceutical formulation in the presence of moisture, and is coated with a polymeric, physiologically tolerated protective coating, where, in the case of stabilization according to b) with alkali metal or alkaline earth metal carbonate, the formulation is free of sugar.
- a compound of a defined formula i.e. ramipril
- WO 93/17685 claims combinations of ACE inhibitors and diuretics such as hydrochlorothiazide.
- Sodium hydrogen carbonate, pregelatinised starch and magnesium stearate are mentioned as excipients. Calcium sulphate is not mentioned.
- compositions of ramipril and piretanide is described in EP 215 357 B1. Calcium sulfate is not mentioned in this patent.
- WO 03/028707 claims a formulation containing ramipril and lactose monohydrate. Calcium sulfate is mentioned in the specification as a possible diluent. Calcium sulfate is not included in any example.
- Calcium sulphate dihydrate is known as an inert diluent in compressed tablets. However, it was surprising that the stability of the tablets proved to be very satisfying.
- the invention provides a pharmaceutical formulation comprising ramipril,
- the pharmaceutical formulation of the present invention comprises typically:
- disintegrant e.g. starch
- binder and/or lubricant e.g. sodium stearyl fumarate
- the formulation optionally also includes a diuretic, such as hydrochlorothiazide or piretanide.
- a diuretic such as hydrochlorothiazide or piretanide.
- the preferred amount of ramipril is 0.5-1.5% w/w
- the amount of Compactrol is 85-90% w/w
- the amount of sodium hydrogen carbonate is 0.5-1.5% w/w
- the amount of starch pregelatinised is 7-13% w/w
- the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
- the preferred amount of ramipril is 1.4-2.5% w/w
- the amount of Compactrol is 78-95% w/w
- the amount of sodium hydrogen carbonate is 1.4-2.5% w/w
- the amount of starch pregelatinised is 7-13% w/w
- the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
- ramipril is 1.4-2.5% w/w
- hydrochlorothiazide is 8.5-10.5% w/w
- the amount of Compactrol is 65-75% w/w
- the amount of sodium hydrogen carbonate is 1.0-2.5% w/w
- the amount of starch pregelatinised is 12-18% w/w
- the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
- the preferred amount of ramipril is 1.5-2.5% w/w
- the amount of piretanide is 1.8-3.0% w/w
- the amount of Compactrol is 65-85% w/w
- the amount of sodium hydrogen carbonate is 3.0-5.0% w/w
- the amount of starch pregelatinised is 10-20% w/w
- the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
- ramipril is susceptible to certain types of degradation, there are several impurities formed during the manufacturing process and storing of the tablet. It is of high importance to minimize this degradation. The strength of different exipients was adjusted until a useful formulation was found.
- Ramipril diketopiperazine is one of the compounds formed via degradation.
- the present formulation proved to be especially stable with regard to formation of the diketopiperazine.
- the example demonstates a very good stability with regard to ramipril diketopiperazine formation.
Abstract
The present invention relates to stable tablet formulations of ramipril, optionally in combination with a diuretic.
Description
- The present invention relates to stable pharmaceutical formulations of ramipril, optionally in combination with a diuretic.
- Ramipril, (2S,3aS,6aS)-1[(S)—N—[(S)-1-carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, 1-ethyl ester is an angiotensin converting enzyme (ACE) inhibitor. Ramipril is used for the treatment of hypertension, heart failure, stroke, myocardial infarction, diabetes and cardiovascular disease.
- Ramipril and the acid form, ramiprilat, is described in EP 0 097 022 B1.
- The preparation of stable pharmaceutical formulations of ramipril is complicated since it is susceptible to certain types of degradation. Ramipril can undergo cyclization via internal nucleophilic attack to form substituted diketopiperazines and also degrade via hydrolysis and oxidation.
- EP 1 501 546 A1 describes stable pharmaceutical formulation for combinations of a statin and an ACE inhibitor. The problem underlying the invention is that if an ACE inhibitor is in the presence of a stabilised statin, the ACE inhibitor decomposes to such extent that even after short storage period the content of decomposition products exceeds the permissible limit of degradation. EP 1 501 546 A1 provides a formulation wherein the statin and the ACE inhibitor are separated by physiologically acceptable inert material. Calcium sulfate is mentioned as a possible inorganic filler in the formulation but it is neither claimed nor mentioned in any example. In fact all the examples are concerned with three-layer tablet, wherein the statin layer and ACE inhibitor layer are separated by a layer of microcrystalline cellulose. Combinations of the ACE inhibitor with a diuretic are not mentioned.
- US 2003/0215526 claims formulations of ACE inhibitor a pharmaceutical composition comprising a therapeutically effective amount of an ACE inhibitor which is susceptible to degradation or its salt; a greater than stoichiometric amount of an alkali or alkaline earth metal carbonate, relative to the amount of ACE inhibitor or its salt, and a pharmaceutically acceptable carrier. The excipient calcium sulphate is not mentioned.
- EP 0 280 999 B1 describes a composition comprising ACE inhibitor (i.e. ramipril), an alkali or alkaline earth metal carbonate and saccharide wherein the ACE inhibitor is stabilized against degradation (cyclization, discoloration and hydrolysis) by means of the other mentioned ingredients. In the specifications the relevant saccharides are lactose and mannitol. Modified starch is mentioned as disintegrant in the specification.
- EP 0 317 878 B1 claims a stable, compressed pharmaceutical formulation containing a compound of a defined formula (i.e. ramipril) wherein, for stabilization before compression, a compound of the formula is a) coated with a polymeric, physiologically tolerated protective coating, or b) mixed with a physiologically tolerated buffer which ensures that a pH in the weakly acidic to weakly alkaline range is set up in a pharmaceutical formulation in the presence of moisture, where sodium bicarbonate is excepted as buffer, or c) mixed with a physiologically tolerated buffer which ensures that a pH in the weakly acid to weakly alkaline range is set up in a pharmaceutical formulation in the presence of moisture, and is coated with a polymeric, physiologically tolerated protective coating, where, in the case of stabilization according to b) with alkali metal or alkaline earth metal carbonate, the formulation is free of sugar.
- WO 93/17685 claims combinations of ACE inhibitors and diuretics such as hydrochlorothiazide. Sodium hydrogen carbonate, pregelatinised starch and magnesium stearate are mentioned as excipients. Calcium sulphate is not mentioned.
- Compositions of ramipril and piretanide is described in EP 215 357 B1. Calcium sulfate is not mentioned in this patent.
- WO 03/028707 claims a formulation containing ramipril and lactose monohydrate. Calcium sulfate is mentioned in the specification as a possible diluent. Calcium sulfate is not included in any example.
- In an attempt to prepare a stable tablet formulation of ramipril, it was discovered that useful formulations can be produced by the use of calcium sulphate dihydrate (e.g. Compactrol) as filler material.
- Properties of calcium sulphate are described in A. H. Kibbe, Handbook of pharmaceutical excipients, 73-76, American Pharmaceutical Association, Washington, and Pharmaceutical Press, London, 2000.
- Calcium sulphate dihydrate is known as an inert diluent in compressed tablets. However, it was surprising that the stability of the tablets proved to be very satisfying.
- The invention provides a pharmaceutical formulation comprising ramipril,
- Compactrol as filling agent, and sodium hydrogen carbonate as stabilization agent.
- The pharmaceutical formulation of the present invention comprises typically:
- a) 0.1-5.0% w/w of ramipril;
- c) 0.1-5.0% w/w of sodium hydrogen carbonate;
and optionally disintegrant (e.g. starch), binder and/or lubricant (e.g. sodium stearyl fumarate). - The formulation optionally also includes a diuretic, such as hydrochlorothiazide or piretanide.
- For the tablet formulation containing 1.25 mg ramipril, the preferred amount of ramipril is 0.5-1.5% w/w, the amount of Compactrol is 85-90% w/w, the amount of sodium hydrogen carbonate is 0.5-1.5% w/w, the amount of starch pregelatinised is 7-13% w/w and the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
- For the tablet formulation containing 2.5 mg, 5 mg and 10 mg ramipril, the preferred amount of ramipril is 1.4-2.5% w/w, the amount of Compactrol is 78-95% w/w, the amount of sodium hydrogen carbonate is 1.4-2.5% w/w, the amount of starch pregelatinised is 7-13% w/w and the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
- For the tablet formulation containing 2.5 mg ramipril/2.5 mg hydrochlorothiazide and 5 mg ramipril/25 mg hydrochlorothiazide, preferred amount of ramipril is 1.4-2.5% w/w, the amount of hydrochlorothiazide is 8.5-10.5% w/w, the amount of Compactrol is 65-75% w/w, the amount of sodium hydrogen carbonate is 1.0-2.5% w/w, the amount of starch pregelatinised is 12-18% w/w and the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
- For the tablet formulation containing 5 mg ramipril and 6 mg piretanide, the preferred amount of ramipril is 1.5-2.5% w/w, the amount of piretanide is 1.8-3.0% w/w, the amount of Compactrol is 65-85% w/w, the amount of sodium hydrogen carbonate is 3.0-5.0% w/w, the amount of starch pregelatinised is 10-20% w/w and the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
- Since ramipril is susceptible to certain types of degradation, there are several impurities formed during the manufacturing process and storing of the tablet. It is of high importance to minimize this degradation. The strength of different exipients was adjusted until a useful formulation was found.
- There are certain criterias that these compounds are not allowed to exceed. The present formulation has proved to be stable.
- Ramipril diketopiperazine is one of the compounds formed via degradation. The present formulation proved to be especially stable with regard to formation of the diketopiperazine.
- The following example is merely illustrative of the present invention and it should not be considered as limiting the scope of the invention.
-
-
Ramipril 0.96% Compactrol 87.08% w/w Sodium hydrogen carbonate 0.96% w/w Starch pregelatinised 10.00% w/w Sodium stearyl fumarate 1.00% w/w -
-
Ramipril 1.9% w/w Compactrol 85.2% w/w Sodium hydrogen carbonate 1.9% w/w Starch pregelatinised 10.0% w/w Sodium stearyl fumarate 1.0% w/w -
-
Ramipril 1.9% w/w Hydrochlorothiazide 9.6% w/w Compactrol 70.5% w/w Sodium hydrogen carbonate 1.9% w/w Starch pregelatinised 15.0% w/w Sodium stearyl fumarate 1.0% w/w -
-
Ramipril 1.9% w/w Piretanide 2.3% w/w Compactrol 76% w/w Sodium hydrogen carbonate 3.7% w/w Starch pregelatinised 15% w/w Sodium stearyl fumarate 1% w/w - Stability of 5 mg and 10 mg tablets prepared in Example 2 and of marketed preparation were tested at 40° C. and 75% relative humidity (RH) for six months. Conversion of ramipril into ramipril diketopiperazine was assayed and measured as relativeomount of initial amount of ramipril.
-
Assay Ramipril diketopiperazine 5 mg Tablets from Ex. 2 4.0% 0.478-1.06% Marketed prepn**. 4.0% 2.77% 10 mg Tablets from Ex. 2 4.0% 0.471-0.806% Marketed prepn**. 4.0% 2.27% **Ramitab ™ ramipril 5 and 10 mg tablets - The example demonstates a very good stability with regard to ramipril diketopiperazine formation.
Claims (11)
1. A tablet formulation comprising:
a) 0.5-5.0% w/w of ramipril;
b) 50-95% w/w of calcium sulphate dihydrate; and
c) 0.1-5.0% W/w of sodium hydrogen carbonate,
optionally in combination with a disintegrant, binder and lubricant and other excipients.
2. The tablet formulation of claim 1 , wherein the calcium sulphate dihydrate is Compactrol.
3. The tablet formulation of claim 1 or claim 2 , additionally in combination with a diuretic.
4. The tablet formulation of claim 3 , wherein the diuretic is hydrochlorothiazide.
5. The tablet formulation of claim 3 , wherein the diuretic is piretanide.
6. The tablet formulation of any of claims 1 to 5 , wherein the disintegrant and binder is pregelatinised starch.
7. The tablet formulation of any of claims 1 to 6 , wherein the lubricant is sodium stearyl fumarate.
8. The tablet formulation of claim 1 or claim 2 containing 1.25 mg ramipril, wherein the amount of ramipril is 0.5-1.5% w/w, the amount of Compactrol is 85-90% w/w, the amount of sodium hydrogen carbonate is 0.5-1.5% w/w, the amount of starch pregelatinised is 7-13% w/w and the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
9. The tablet formulation of claim 1 or claim 2 containing 2.5 mg, 5 mg or 10 mg ramipril, wherein the amount of ramipril is 1.4-2.5% w/w, the amount of Compactrol is 78-95% w/w, the amount of sodium hydrogen carbonate is 1.4-2.5% w/w, the amount of starch pregelatinised is 7-13% w/w and the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
10. The tablet formulation of any of claims 1 to 4 , containing 2.5 mg ramipril/2.5 mg hydrochlorothiazide or 5 mg ramipril/25 mg hydrochlorothiazide, wherein the amount of ramipril is 1.4-2.5% w/w, the amount of hydrochlorothiazide is 8.5-10.5% w/w, the amount of Compactrol is 65-75% w/w, the amount of sodium hydrogen carbonate is 1.0-2.5% w/w, the amount of starch pregelatinised is 12-18% w/w and the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
11. The tablet formulation of any of claims 1 to 3 and 5 , containing 5 mg ramipril and 6 mg piretanide, the preferred amount of ramipril is 1.5-2.5% w/w, the amount of piretanide is 1.8-3.0% w/w, the amount of Compactrol is 65-85% w/w, the amount of sodium hydrogen carbonate is 3.0-5.0% w/w, the amount of starch pregelatinised is 10-20% w/w and the amount of sodium stearyl fumarate is 0.5-1.5% w/w.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/777,849 US7589064B2 (en) | 2004-03-24 | 2007-07-13 | Formulations of ramipril |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IS7196A IS2197B (en) | 2004-03-24 | 2004-03-24 | Ramipril Pharmaceutical Compositions |
IS7196 | 2004-03-24 | ||
IS7772 | 2005-03-23 | ||
IS7772A IS2204B (en) | 2005-03-23 | 2005-03-23 | Pharmaceutical formulations of ramipril and pyranetide |
PCT/IS2005/000008 WO2005067887A2 (en) | 2004-03-24 | 2005-03-23 | Formulations of ramipril |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IS2005/000008 A-371-Of-International WO2005067887A2 (en) | 2004-03-24 | 2005-03-23 | Formulations of ramipril |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/777,849 Continuation US7589064B2 (en) | 2004-03-24 | 2007-07-13 | Formulations of ramipril |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080234353A1 true US20080234353A1 (en) | 2008-09-25 |
Family
ID=34796871
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/593,627 Abandoned US20080234353A1 (en) | 2004-03-24 | 2005-03-23 | Formulations of Ramipril |
US11/777,849 Expired - Fee Related US7589064B2 (en) | 2004-03-24 | 2007-07-13 | Formulations of ramipril |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/777,849 Expired - Fee Related US7589064B2 (en) | 2004-03-24 | 2007-07-13 | Formulations of ramipril |
Country Status (4)
Country | Link |
---|---|
US (2) | US20080234353A1 (en) |
EP (1) | EP1734931A2 (en) |
EA (1) | EA011862B1 (en) |
WO (1) | WO2005067887A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070254030A1 (en) * | 2004-03-24 | 2007-11-01 | Reynir Eyjolfsson | Formulations of Ramipril |
US20070259941A1 (en) * | 2005-10-28 | 2007-11-08 | Selamine Limited | Ramipril formulation |
US20100062062A1 (en) * | 2008-09-11 | 2010-03-11 | Aethos Pharmaceuticals, Inc. | Stabilized Coating for Pharmaceutical Formulations |
WO2011034513A1 (en) | 2009-08-17 | 2011-03-24 | Mahmut Bilgic | The granules with improved solubility and stability |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0518129D0 (en) * | 2005-09-06 | 2005-10-12 | Arrow Int Ltd | Ramipril formulation |
AU2006303068A1 (en) * | 2005-10-21 | 2007-04-26 | Selamine Limited | Ramipril formulation with increased stability |
US20070098782A1 (en) * | 2005-10-28 | 2007-05-03 | Selamine Limited | Ramipril Formulation |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
AU2009290410A1 (en) * | 2008-07-30 | 2010-03-18 | Panacea Biotec Limited | Modified release ramipril compositions and uses thereof |
RU2479310C2 (en) * | 2011-02-09 | 2013-04-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Pharmaceutical composition for treating arterial hypertension and congestive cardiac failure and method for preparing it |
UA113977C2 (en) | 2012-02-17 | 2017-04-10 | PHARMACEUTICAL COMPOSITION WITH IMPROVED STABILITY | |
RU2618471C2 (en) * | 2012-12-03 | 2017-05-03 | Закрытое Акционерное Общество "Вертекс" | Oral pharmaceutical composition of diuretics and ace inhibitor in micronized form, drug and its application |
HUP1300496A2 (en) | 2013-08-16 | 2015-03-02 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Stable pharmaceutical composition |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
US5151433A (en) * | 1987-11-24 | 1992-09-29 | Hoechst Aktiengesellschaft | Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations |
US6096779A (en) * | 1995-02-22 | 2000-08-01 | Hoechst Pharmaceuticals & Chemicals K.K. | Amorphous piretanide, piretanide polymorphs, process for their preparation and their use |
US20030148960A1 (en) * | 1995-02-10 | 2003-08-07 | G.D. Searle & Co. | Combination therapy of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist for treatment of cardiovascular disease |
US20030215526A1 (en) * | 2002-03-08 | 2003-11-20 | Scott Stofik | Stable formulations of angiotensin converting enzyme (ACE) inhibitors |
US20030225124A1 (en) * | 1999-08-31 | 2003-12-04 | Spiridon Spireas | Stable formulations of ACE inhibitors, and methods for preparation thereof |
US6667060B1 (en) * | 1999-03-31 | 2003-12-23 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
US20040137054A1 (en) * | 2002-05-03 | 2004-07-15 | Alexandra Hager | Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors |
US6869963B2 (en) * | 2003-07-11 | 2005-03-22 | Sandoz Ag | Stable pharmaceutical compositions containing an ACE inhibitor |
US20050069586A1 (en) * | 2003-06-26 | 2005-03-31 | Julia Hrakovsky | Stable pharmaceutical compositions of 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivatives |
US20050118259A1 (en) * | 2002-01-15 | 2005-06-02 | Renir Eyjolfsson | Formulations of quinapril and related ace nhibitors |
US20050192315A1 (en) * | 2004-02-06 | 2005-09-01 | Active Biotech Ab | New compositions containing quinoline compounds |
US20050202081A1 (en) * | 2002-01-15 | 2005-09-15 | Deepak Bahl | Stable pharmaceutical compositions comprising ace inhibitor(s) |
US20070053975A1 (en) * | 2005-09-06 | 2007-03-08 | Selamine Limited | Ramipril formulation |
US20070098782A1 (en) * | 2005-10-28 | 2007-05-03 | Selamine Limited | Ramipril Formulation |
US20070254030A1 (en) * | 2004-03-24 | 2007-11-01 | Reynir Eyjolfsson | Formulations of Ramipril |
US20070259941A1 (en) * | 2005-10-28 | 2007-11-08 | Selamine Limited | Ramipril formulation |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3226768A1 (en) | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF |
DE3532036A1 (en) * | 1985-09-09 | 1987-03-26 | Hoechst Ag | PHARMACEUTICAL PREPARATION FOR TREATING HIGH PRESSURE |
US5256687A (en) | 1985-09-09 | 1993-10-26 | Hoechst Aktiengesellschaft | Pharmaceutical composition for the treatment of high blood pressure |
US4830853A (en) | 1986-10-20 | 1989-05-16 | Warner-Lambert Company | Drug compositions stabilized against oxidation |
DK9200258U4 (en) * | 1992-03-11 | 1993-07-23 | Merck & Co Inc | Pharmaceutical preparation containing enalapril for use in hypertension |
GB9401892D0 (en) | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
WO1996031197A1 (en) | 1995-04-03 | 1996-10-10 | Abbott Laboratories | Homogeneous mixtures of low temperature-melting drugs and additives for controlled release |
US5733578A (en) * | 1995-11-15 | 1998-03-31 | Edward Mendell Co., Inc. | Directly compressible high load acetaminophen formulations |
AU713849B2 (en) | 1995-12-27 | 1999-12-09 | Janssen Sciences Ireland Uc | Bioadhesive solid dosage form |
HU222109B1 (en) | 1996-09-10 | 2003-04-28 | EGIS Gyógyszergyár Rt. | Tablets containing captopril and process for producing them |
US20030027837A1 (en) | 1998-12-08 | 2003-02-06 | Sherman Bernard Charles | Pharmaceutical compositions comprising quinapril magnesium |
US20040157911A1 (en) | 1999-08-31 | 2004-08-12 | Spiridon Spireas | Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof |
US6555551B1 (en) | 1999-08-31 | 2003-04-29 | Mutual Pharmaceutical Co., Inc. | Stable formulations of ACE inhibitors, and methods for preparation thereof |
US20060034937A1 (en) | 1999-11-23 | 2006-02-16 | Mahesh Patel | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6458384B2 (en) | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
DE10038364A1 (en) | 2000-08-05 | 2002-05-02 | Hexal Ag | Pharmaceutical effervescent formulation containing ramipril |
FR2824477B1 (en) | 2001-05-09 | 2005-09-09 | Ethypharm Lab Prod Ethiques | ENVELOPED GRANULES BASED ON INHIBITOR OF THE ANFIOTENSIN CONVERTING ENZYME, PROCESS FOR THEIR PREPARATION AND ORODISPERSIBLE TABLETS CONTAINING COATED GRANULES |
GB0117619D0 (en) | 2001-07-19 | 2001-09-12 | Phoqus Ltd | Pharmaceutical dosage form |
US6576256B2 (en) | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
CA2357982A1 (en) * | 2001-09-28 | 2003-03-28 | Bernard Charles Sherman | Solid compositions comprising ramipril |
ATE516356T1 (en) * | 2001-12-21 | 2011-07-15 | Biosynexus Inc | SUPPORTED LYSOSTAPHIN MOLECULE WITH IMPROVED STAPHYLOLYTIC EFFECT |
FR2834893B1 (en) | 2002-01-23 | 2004-02-27 | Servier Lab | ORODISPERSIBLE PHARMACEUTICAL COMPOSITION OF PERINDOPRIL |
KR100540035B1 (en) * | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | Multi-stage oral drug controlled-release system |
US6844361B2 (en) | 2002-02-04 | 2005-01-18 | Aventis Pharma Deutschland Gmbh | Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor |
AU2003217916A1 (en) * | 2002-03-08 | 2003-09-22 | Teva Pharmeceuticals Usa, Inc. | Stable formulations of angiotensin converting enzyme (ace) inhibitors |
JP2006511567A (en) | 2002-12-16 | 2006-04-06 | キング・ファーマシューティカルズ・インコーポレーテッド | Methods and dosage forms for reducing heart attacks in hypertensive individuals using diuretics or using a combination of diuretics and ACE inhibitors |
US20060177498A1 (en) | 2003-01-22 | 2006-08-10 | Ramaswami Bharatrajan | Solid pharmaceutical composition comprising ramipril |
EP1605916A4 (en) | 2003-02-12 | 2012-02-22 | R & P Korea Co Ltd | Solvent system of hardly soluble drug with improved elution rate |
ES2665464T3 (en) | 2003-03-28 | 2018-04-25 | Sigmoid Pharma Limited | Solid oral dosage form containing seamless microcapsules |
US20060188568A1 (en) | 2003-10-30 | 2006-08-24 | Lupin Limited | Stable formulations of ace inhibitors and methods for preparation thereof |
GB2394660A (en) | 2003-12-17 | 2004-05-05 | Niche Generics Ltd | Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide |
ES2241478B1 (en) | 2004-02-13 | 2006-11-16 | Lacer S.A. | PHARMACEUTICAL PREPARATION FOR THE SUSTAINED RELEASE OF A PHARMACEUTICALLY ACTIVE PRINCIPLE. |
DE102004008804A1 (en) | 2004-02-20 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Multilayer tablet |
GB2411355B (en) | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
US20060045911A1 (en) | 2004-08-27 | 2006-03-02 | Sun Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations |
EP1817007A2 (en) | 2004-11-05 | 2007-08-15 | King Pharmaceuticals Research and Development Inc. | Stabilized individually coated ramipril particles, compositions and methods |
WO2006074051A2 (en) | 2004-12-30 | 2006-07-13 | Diakine Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION |
-
2005
- 2005-03-23 US US10/593,627 patent/US20080234353A1/en not_active Abandoned
- 2005-03-23 EA EA200601759A patent/EA011862B1/en unknown
- 2005-03-23 WO PCT/IS2005/000008 patent/WO2005067887A2/en active Application Filing
- 2005-03-23 EP EP05718970A patent/EP1734931A2/en not_active Withdrawn
-
2007
- 2007-07-13 US US11/777,849 patent/US7589064B2/en not_active Expired - Fee Related
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
US5151433A (en) * | 1987-11-24 | 1992-09-29 | Hoechst Aktiengesellschaft | Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations |
US20030148960A1 (en) * | 1995-02-10 | 2003-08-07 | G.D. Searle & Co. | Combination therapy of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist for treatment of cardiovascular disease |
US6096779A (en) * | 1995-02-22 | 2000-08-01 | Hoechst Pharmaceuticals & Chemicals K.K. | Amorphous piretanide, piretanide polymorphs, process for their preparation and their use |
US6667060B1 (en) * | 1999-03-31 | 2003-12-23 | Janssen Pharmaceutica N.V. | Pregelatinized starch in a controlled release formulation |
US20030225124A1 (en) * | 1999-08-31 | 2003-12-04 | Spiridon Spireas | Stable formulations of ACE inhibitors, and methods for preparation thereof |
US20050118259A1 (en) * | 2002-01-15 | 2005-06-02 | Renir Eyjolfsson | Formulations of quinapril and related ace nhibitors |
US20050202081A1 (en) * | 2002-01-15 | 2005-09-15 | Deepak Bahl | Stable pharmaceutical compositions comprising ace inhibitor(s) |
US20030215526A1 (en) * | 2002-03-08 | 2003-11-20 | Scott Stofik | Stable formulations of angiotensin converting enzyme (ACE) inhibitors |
US20040137054A1 (en) * | 2002-05-03 | 2004-07-15 | Alexandra Hager | Stable pharmaceutical formulation for a combination of a statin and an ace-inhibitors |
US20050069586A1 (en) * | 2003-06-26 | 2005-03-31 | Julia Hrakovsky | Stable pharmaceutical compositions of 2-aza-bicyclo [3.3.0]-octane-3-carboxylic acid derivatives |
US6869963B2 (en) * | 2003-07-11 | 2005-03-22 | Sandoz Ag | Stable pharmaceutical compositions containing an ACE inhibitor |
US20050192315A1 (en) * | 2004-02-06 | 2005-09-01 | Active Biotech Ab | New compositions containing quinoline compounds |
US20070254030A1 (en) * | 2004-03-24 | 2007-11-01 | Reynir Eyjolfsson | Formulations of Ramipril |
US20070053975A1 (en) * | 2005-09-06 | 2007-03-08 | Selamine Limited | Ramipril formulation |
US20070098782A1 (en) * | 2005-10-28 | 2007-05-03 | Selamine Limited | Ramipril Formulation |
US20070259941A1 (en) * | 2005-10-28 | 2007-11-08 | Selamine Limited | Ramipril formulation |
US20080108688A1 (en) * | 2005-10-28 | 2008-05-08 | Selamine Limited | Ramipril formulation |
US20080108687A1 (en) * | 2005-10-28 | 2008-05-08 | Selamine Limited | Ramipril formulation |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070254030A1 (en) * | 2004-03-24 | 2007-11-01 | Reynir Eyjolfsson | Formulations of Ramipril |
US7589064B2 (en) | 2004-03-24 | 2009-09-15 | Actavis Group Hf. | Formulations of ramipril |
US20070259941A1 (en) * | 2005-10-28 | 2007-11-08 | Selamine Limited | Ramipril formulation |
US20100062062A1 (en) * | 2008-09-11 | 2010-03-11 | Aethos Pharmaceuticals, Inc. | Stabilized Coating for Pharmaceutical Formulations |
WO2011034513A1 (en) | 2009-08-17 | 2011-03-24 | Mahmut Bilgic | The granules with improved solubility and stability |
Also Published As
Publication number | Publication date |
---|---|
US7589064B2 (en) | 2009-09-15 |
US20070254030A1 (en) | 2007-11-01 |
WO2005067887A2 (en) | 2005-07-28 |
EA011862B1 (en) | 2009-06-30 |
EP1734931A2 (en) | 2006-12-27 |
EA200601759A1 (en) | 2007-04-27 |
WO2005067887A3 (en) | 2005-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7589064B2 (en) | Formulations of ramipril | |
US20160129008A1 (en) | Solid Dosage Form of Olmesartan Medoxomil and Amlodipine | |
US20030215526A1 (en) | Stable formulations of angiotensin converting enzyme (ACE) inhibitors | |
US20060045911A1 (en) | Stable pharmaceutical formulations | |
US20120107397A1 (en) | Pharmaceutical compositions of valsartan | |
US20080108687A1 (en) | Ramipril formulation | |
EA015682B1 (en) | Pharmaceutical composition | |
EP1429748B1 (en) | Solid compositions comprising ramipril | |
KR20080094837A (en) | Fluvastatin sodium pharmaceutical compositions | |
US20100035955A1 (en) | Stabilised Composition Comprising ACE Inhibitors | |
US20070155780A1 (en) | Stabilized composition containing 4-amino-5-chloro-n-[(1r, 3r, 5s)-8-methyl-8-azabicyclo[3.2.1]oct-3-y1]-2-[1-methylbut-2-ynyloxy]benzamide | |
US7959948B2 (en) | Pharmaceutical composition of quetiapine fumarate | |
JP2009533461A (en) | Stable pharmaceutical composition of 2-aza-bicyclo [3.3.0] -octane-3-carboxylic acid derivative | |
WO1998026765A1 (en) | Stabilized pharmaceutical compositions and process for the preparation thereof | |
KR20200073676A (en) | Solid dispersion comprising valsartan and sacubitril and pharmaceutical composition comrising same and method of preparation therof | |
JP5113476B2 (en) | Temocapril hydrochloride tablets with excellent storage stability | |
TWI674907B (en) | A combination formulation comprising hmg-coa reductase inhibitor and calcium channel blocker | |
US20150209290A1 (en) | Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate | |
EP1906931B1 (en) | Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof | |
EP1178793B1 (en) | Stable solid pharmaceutical compositions containing enalapril maleate | |
RU2479310C2 (en) | Pharmaceutical composition for treating arterial hypertension and congestive cardiac failure and method for preparing it | |
WO2008001184A2 (en) | Solid composition | |
US6296871B1 (en) | Stable solid pharmaceutical compositions containing enalapril maleate | |
JP7437039B2 (en) | tablet | |
US20080102134A1 (en) | Controlled release color stable pharmaceutical dosage form of hmg-coa reductase inhibitors, free of alkalizing or buffering agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ACTAVIS GROUP HF., ICELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:EYJOLFSSON, REYNIR;REEL/FRAME:018705/0857 Effective date: 20061123 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |